AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$TEVA

Shields Matthew sold $322K of TEVA

Shields Matthew (EVP, Global Operations) sold 9,989 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $32.19 ($0.32M total) on 2026-06-18.

Original reporting
SEC EDGAR · Shields Matthew
Published Jun 22, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
low confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings (0 shares), which may slightly influence sentiment but does not change TEVA fundamentals in the text.

02

Market read

Traders may note the insider selling signal, but the disclosure alone is unlikely to be a standalone catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the article also lacks context on total holdings history, tax events, or whether other insiders made offsetting buys.

Relevance 4/10Novelty 4/10Timing: after-hours/filing date (2026-06-22) for an insider sale executed 2026-06-18

Background

This is an SEC Form 4 insider transaction for TEVA, reported by Matthew Shields (EVP, Global Operations).

Company-level read

Ticker impact

$TEVANeutralLow confidence
Context

TEVA disclosed an EVP Global Operations open-market sale of 9,989 shares at $32.1901 on 2026-06-18 via Form 4.

Expected impact

Likely limited near-term impact; any effect would be small and quickly absorbed unless followed by additional disclosures.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational/financial guidance change.

Market effects

Sector

No sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated; TEVA is the only subject with a disclosed transaction.

Global

Minimal; no deal, regulatory action, or operational update is described.

Counterpoint

What could challenge this read

The sale could be liquidity/portfolio rebalancing rather than a bearish signal, especially since the transaction is labeled open-market and the filing provides no stated reason.

Key entities

  • issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Shields Matthew

    EVP, Global Operations who sold 9,989 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min